First-in-class erythroid maturation agent in development for treatment of serious and chronic anemias.

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis.

Discovered by scientists at Acceleron, luspatercept is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.